News

Filter

Current filters:

simeprevir

1 to 9 of 14 results

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C

24-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

25-10-2013

Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Janssen files for European approval of hep C candidate simeprevir

25-04-2013

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top